MedTrace Logo

Randomized Study for Efficacy and Safety of Ranibizumab 0.5mg in Treat-extend and Monthly Regimens in Patients With nAMD

NCT01948830 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 650

Last updated 2017-04-17

Study results available
· View outcomes & findings →

Summary

This study was designed to evaluate the efficacy and safety of two different regimens of 0.5 mg ranibizumab given as intravitreal injection in patients with neovascular age-related macular degeneration

Conditions

  • Age-related Macular Degeneration
  • Choroidal Neovascularization

Interventions

DRUG

Ranibizumab 0.5mg

0.5 mg ranibizumab (intravitreal injections) prefilled syringe)

DRUG

Ranibizumab 0.5mg

0.5 mg ranibizumab (intravitreal injections) prefilled syringe)

Sponsors & Collaborators

Principal Investigators

  • Novartis Pharmaceuticals · Novartis Pharmaceuticals

Study Design

Allocation
RANDOMIZED
Purpose
SUPPORTIVE_CARE
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
50 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-12-17
Primary Completion
2015-11-19
Completion
2015-11-19

Countries

  • Belgium
  • Chile
  • Croatia
  • Denmark
  • Egypt
  • Germany
  • Hungary
  • India
  • Israel
  • Italy
  • Portugal
  • Russia
  • Slovakia
  • Slovenia
  • South Korea
  • Spain
  • Switzerland
  • Turkey (Türkiye)
  • United Kingdom

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01948830 on ClinicalTrials.gov